ABT
Abbott Laboratories
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 8.9B | 9.6B | 8.6B | 7.3B | 9.6B | 10.5B | 7.9B | 6.1B | 6.3B | 5.6B | 3.2B | 3.0B | 3.7B | 3.3B | 9.3B | 9.0B | 8.7B | 7.3B | 7.0B | 5.2B |
| 2.10B | 2.17B | 2.21B | 2.20B | 1.78B | 1.89B | 2.18B | 1.64B | 1.39B | 1.14B | 1.12B | 1.11B | 1.08B | 1.15B | 1.80B | 1.49B | 1.02B | 1.09B | 1.29B | 1.66B | |
| Free cash flow | 6.76B | 7.40B | 6.35B | 5.06B | 7.80B | 8.65B | 5.72B | 4.50B | 4.91B | 4.44B | 2.08B | 1.86B | 2.60B | 2.18B | 7.52B | 7.48B | 7.72B | 6.19B | 5.71B | 3.53B |
| Depreciation and amortization | 3.91B | 3.12B | 3.22B | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B | 1.47B | 1.55B | 1.72B | 2.78B | 3.04B | 2.62B | 2.09B | 1.84B | 1.85B |
| Stock-based compensation | 735M | 664M | 673M | 644M | 685M | 640M | 546M | 519M | 477M | 406M | 310M | 292M | 246M | 262M | 433M | 383M | 387M | 366M | 347M | 430M |
| Buybacks | 1.54B | 0.89B | 1.30B | 1.23B | 3.80B | 2.30B | 0.40B | 0.72B | 0.24B | 0.12B | 0.52B | 2.24B | 2.20B | 1.61B | 2.36B | 77M | 0.87B | 0.83B | 1.08B | 1.06B |
| Dividends paid | 4.32B | 4.12B | 3.84B | 3.56B | 3.31B | 3.20B | 2.56B | 2.27B | 1.97B | 1.85B | 1.54B | 1.44B | 1.34B | 0.88B | 3.18B | 2.94B | 2.67B | 2.41B | 2.17B | 1.96B |
| Dividends per share | 2.52 | 2.40 | 2.24 | 2.08 | 1.92 | — | — | — | — | — | — | — | — | — | — | 1.92 | 1.76 | 1.60 | — | — |
| Free cash flow margin | 14.0% | 16.7% | 15.1% | 12.6% | 17.9% | 20.1% | 16.5% | 14.1% | 16.0% | 16.2% | 10.0% | 9.1% | 12.8% | 11.1% | 39.5% | 34.9% | 22.0% | 20.1% | 19.3% | 13.6% |